On the stock market since 1995, it operates in the world of money and finance. It has 7,405 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
For a bank, strength is measured by capital buffers and reserves — not cash minus debt.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The stock has been running stronger than the market lately.
Financial Strength: The capital buffer looks thin next to its class; less room to absorb a rough stretch.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The company sells $6.4B a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 44 buys and 36 sells. Management buying with its own money is usually read as a good sign.
It pays out $0.85 per share each year — regular cash for whoever holds the stock.
A loss of $281.7M against $6.4B in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 7/100.
The growth engine is running at low revs right now. Report-card grade: 15/100.
On our five-subject report card, IVZ sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: IVZ has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.